8 May 1997 Light-emitting diode versus laser irradiation phototherapy with lutetium texaphyrin (PCI-0123)
Author Affiliations +
Lutetium texaphyrin (PCI-0123) is presently in clinical trials for the treatment of neoplasms. An argon-pumped dye laser has mostly been used to generate light for PCI-0123 photoactivation. However, lasers are expensive and produce a limited area of illumination, so the efficacy of light emitting diodes (LEDs) was investigated. An LED array was developed so that the spectral emission matched the far red absorption spectrum of PCI-0123. A preclinical PDT efficacy study comparing the laser and the LED was undertaken using EMT6-bearing animals. The LED and laser light sources were statistically comparable in eradicating the murine mammary sarcomas using PCI-0123 as the photosensitizer.
© (1997) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Kathryn W. Woodburn, Kathryn W. Woodburn, Stuart W. Young, Stuart W. Young, Fan Qing, Fan Qing, Dale R. Miles, Dale R. Miles, Patricia A. Thiemann, Patricia A. Thiemann, } "Light-emitting diode versus laser irradiation phototherapy with lutetium texaphyrin (PCI-0123)", Proc. SPIE 2972, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy VI, (8 May 1997); doi: 10.1117/12.273486; https://doi.org/10.1117/12.273486


Back to Top